Amidine-Substituted Monobactams Against β-Lactamase Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of bacterial resistance to β-lactam antibiotics, particularly driven by β-lactamases, threatens the effectiveness of current treatments for Gram-negative bacterial infections, with limited therapeutic options available for multi-drug-resistant pathogens.
Innovation Solution
Development of novel amidine substituted monobactam compounds, which can be administered alone or in combination with β-lactamase inhibitors, to combat bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional β-lactam antibiotics are used, then treatment of bacterial infections is effective, but bacterial resistance emerges due to β-lactamase enzymes
Solution Approach 1:
The patent modifies the chemical structure of monobactam compounds by introducing amidine substituents at specific positions (R1, R2, R3) and varying molecular parameters such as stereochemistry and side chain composition. These parameter changes enhance resistance to hydrolysis by β-lactamases while preserving antibacterial activity, directly addressing the effectiveness-resistance contradiction
Solution Approach 2:
The invention creates composite molecular structures combining the monobactam core with amidine functional groups and various substituent patterns. This composite approach generates compounds with dual properties: maintained β-lactam activity against bacteria and improved stability against enzymatic degradation, resolving the contradiction between treatment effectiveness and resistance development
2Reliability
If monobactam compounds are developed to overcome resistance, then activity against Gram-negative bacteria improves, but activity against Pseudomonas and Acinetobacter remains poor
Solution Approach 1:
The patent designs monobactam derivatives with amidine substituents that confer broad-spectrum activity across multiple Gram-negative bacterial families including Enterobacteriaceae, Pseudomonas, and Acinetobacter. The molecular structure achieves multi-functionality by simultaneously providing resistance to β-lactamases and enhanced penetration or binding affinity for diverse Gram-negative targets, thereby expanding versatility while maintaining reliability
3Adaptability or versatility
If new β-lactam structures are designed to break resistance, then therapeutic options increase, but development complexity increases
Solution Approach 1:
The patent employs a segmented molecular design approach where the monobactam core structure is preserved and modified with discrete amidine substituent modules at specific positions. This segmentation allows systematic exploration of structure-activity relationships by varying individual substituents (R1, R2, R3 groups) while maintaining the fundamental pharmacophore, thereby increasing therapeutic options without proportionally increasing overall structural complexity
Data Source
AI summary
This disclosure relates to the medical field, more specifically to novel β-lactam compounds of formula (I), and their preparation and use as antibiotic agents in methods for the treatment of bacterial infections.